PDF(258 KB)
Nanodelivery-mediated Remodeling of Tumor Stromal Cells to Reverse the Immunosuppressive Tumor Microenvironment: From a Cell-Centric View to a Constraint-based Conceptual Framework
Siyuan Chen¹, Mingzhe Zhao²
Cancer Immuno Perspectives ›› 2026, Vol. 1 ›› Issue (1) : 67-90.
PDF(258 KB)
PDF(258 KB)
Nanodelivery-mediated Remodeling of Tumor Stromal Cells to Reverse the Immunosuppressive Tumor Microenvironment: From a Cell-Centric View to a Constraint-based Conceptual Framework
Siyuan Chen¹, Mingzhe Zhao²*
Reversing the immunosuppressive tumor microenvironment (ITME) represents a core proposition for overcoming resistance to immune checkpoint inhibitors (ICIs). Tumor-associated macrophages (TAMs), cancer-associated fibroblasts (CAFs), myeloid-derived suppressor cells (MDSCs), and regulatory T cells (Tregs) collectively sustain the ITME via functional complementation and compensation, such that interventions targeting a single cell type are frequently buffered by tumor network effects. Nanoscale drug-delivery systems (nano-DDSs) serve as powerful enabling tools for functional modulation of stromal cells owing to their capacity for payload protection, multifunctional integration, and designable targeting modification. Nevertheless, a set of delivery constraints that cannot be deduced solely from target-related biology lies between the identification of intervenable functional nodes and the achievement of effective in-vivo intervention by nanocarriers. Following the analytical pipeline of functional node → delivery constraint → carrier response → mismatch-based audit, this review re-interprets how immunosuppressive functions of the four stromal cell types translate into design requirements for nanocarriers. Four core delivery constraints are extracted: reachability, penetration, selectivity, and intracellular site-of-action constraints. Using these constraints as evaluation lenses, we audit four major nanocarrier categories: lipid-based, polymeric, biomembrane-coated, and inorganic/hybrid platforms. The audit demonstrates that no single platform can simultaneously satisfy all four constraints, and systematic alignment gaps exist between inherent platform strengths and practical demands of given functional nodes. Four representative classes of mismatches are summarized: substituting target-binding affinity for delivery reachability, substituting cell depletion for functional reprogramming, intervening against a single cell type within a functionally redundant network, and extrapolating preclinical stromal architecture to patient tumor architecture. Published clinical and translational evidence corroborates these mismatch-oriented diagnoses. Accordingly, a constraint-matching-centered research framework is proposed. We advocate shifting the evaluative anchor from "whether a nanocarrier reaches a given stromal cell subset" toward "whether a nanocarrier produces attributable intervention effects at the spatial, cell-state, and network contexts defined by the target functional node". This work provides new insights for translational development of stroma-targeted nanomedicines.
tumor microenvironment / stromal cells / nanodelivery / functional node / delivery constraint / mismatch
/
| 〈 |
|
〉 |